Every breakthrough therapy creates another difficult purchasing decision. As specialty medications, gene therapies, precision medicine, and biosimilars reshape the pharmacy landscape, employers must determine how to balance innovation, affordability, and long-term sustainability. This session explores practical strategies for managing the pipeline while maintaining access to high-value care.

Independent claims data and independent audits are becoming two of the most valuable tools available to employers. This session explores how leading organizations use pharmacy analytics to improve vendor accountability, evaluate performance, and make smarter purchasing decisions—and how employers are moving beyond rebate guarantees to conduct independent audits that uncover contract discrepancies, pricing variation, and missed savings without cutting benefits.

GLP-1 therapies have fundamentally changed employer pharmacy strategy. As manufacturers, digital health companies, and new direct-to-consumer and direct-to-employer models redefine how employees access treatment, employers are facing difficult decisions about affordability, access, member expectations, and fiduciary responsibility. This closing discussion explores how organizations are evaluating emerging care models, responding to growing employee demand, and making strategic decisions that balance access, affordability, and sustainable coverage.